I expect that most shareholders have now factored in that Safety Data will show an excellent score for Cvac.
The important point missing in this thread is what M.Lehmann stated at the Shareholder Meeting... that safety is the most important asset of the company.
Without it, there is no Cvac and there certainly won't be any attraction for large pharmas.
I already expect excellent safety data but nonetheless, the significance of that data is not lost on me.
recruitment for can003 trial phase, page-20
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 31.8¢ | $845.3K | 2.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 140318 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 14222 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |